Immune modulation in Pompe disease treated with enzyme replacement therapy, Expert Rev Clin Immunol, vol.8, pp.497-499, 2012. ,
CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy, Genet Med, vol.17, pp.912-918, 2015. ,
) scAAV9 intracisternal delivery results in efficient gene transfer to the central nervous system of a feline model of motor neuron disease, Hum Gene Ther, vol.24, pp.670-682, 2013. ,
Intracisternal delivery of AAV9 results in oligodendrocyte and motor neuron transduction in the whole central nervous system of cats, Gene Ther, vol.21, pp.522-528, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01189927
Acute progression of neuromuscular findings in infantile Pompe disease, Pediatr Neurol, vol.42, pp.455-458, 2010. ,
Pompe disease gene therapy, Hum Mol Genet, vol.20, pp.61-68, 2011. ,
Pompe disease: design, methodology, and early findings from the Pompe registry, Mol Genet Metab, vol.103, pp.1-11, 2011. ,
Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with Pompe disease, Hum Gene Ther Clin Dev, vol.25, pp.134-163, 2014. ,
Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts, PathoGenetics, vol.1, p.6, 2008. ,
Pre-clinical study of 21 approved drugs in the mdx mouse, Neuromuscul Disord, vol.21, pp.313-327, 2011. ,
Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations, Am J Med Genet C Semin Med Genet, vol.160, pp.69-79, 2012. ,
Detection of a homozygous D645E mutation of the acid alpha-glucosidase gene and glycogen deposition in tissues in a second-trimester fetus with infantile glycogen storage disease type II, Prenat Diagn, vol.24, pp.231-232, 2004. ,
Gene therapy for the neurological manifestations in lysosomal storage disorders, J Lipid Res, vol.55, pp.1827-1838, 2014. ,
Brain development in infantileonset Pompe disease treated by enzyme replacement therapy, Pediatr Res, vol.60, pp.349-352, 2006. ,
Altered activation of the tibialis anterior in individuals with Pompe disease: implications for motor unit dysfunction, Muscle Nerve, vol.51, pp.877-883, 2015. ,
Teaching tolerance: new approaches to enzyme replacement therapy for Pompe disease, Hum Vaccin Immunother, vol.8, pp.1459-1464, 2012. ,
Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II, Hum Gene Ther, vol.16, pp.68-80, 2005. ,
Neural deficits contribute to respiratory insufficiency in Pompe disease, Proc Natl Acad Sci U S A, vol.106, pp.9419-9424, 2009. ,
Intracerebroventricular injection of adeno-associated virus 6 and 9 vectors for cell type-specific transgene expression in the spinal cord, Hum Gene Ther, vol.25, pp.109-120, 2014. ,
Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II, Hum Mol Genet, vol.17, pp.3876-3886, 2008. ,
Quantification of brain lipids by FTIR spectroscopy and partial least squares regression, Spectrochim Acta A Mol Biomol Spectrosc, vol.71, pp.2069-2075, 2009. ,
Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector, Gene Ther, vol.6, pp.1175-1178, 1999. ,
Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease, Mol Ther, vol.21, pp.1661-1667, 2013. ,
Peripheral nerve and neuromuscular junction pathology in Pompe disease, Hum Mol Genet, vol.24, pp.625-636, 2015. ,
Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs, Gene Ther, vol.19, pp.852-859, 2012. ,
The respiratory neuromuscular system in Pompe disease, Respir Physiol Neurobiol, vol.189, pp.241-249, 2013. ,
Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates, Jude Samulski R, vol.20, pp.450-459, 2013. ,
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy, J Clin Invest, 2013. ,
Early detection of the chemical changes occurring during the induction and prevention of autoimmune-mediated demyelination detected by FT-IR imaging, NeuroImage, vol.49, pp.1180-1189, 2010. ,
Glycogen storage disease type II: acid alphaglucosidase (acid maltase) deficiency. In: Graw-Hill NYM (ed) The metabolic and molecular bases of inherited disease, pp.2289-3420, 2001. ,
Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature, Mol Genet Metab, vol.106, pp.462-469, 2012. ,
Efficient central nervous system AAVrh10-mediated intrathecal gene transfer in adult and neonate rats, Gene Ther, vol.22, pp.316-324, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01138008
Fully deleted adenovirus persistently expressing GAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice, Mol Ther, vol.13, pp.127-134, 2006. ,
The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management, Am J Med Genet C Semin Med Genet, vol.160, pp.1-7, 2012. ,
Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease, FASEB J, vol.28, pp.2171-2176, 2014. ,
2012) ?2 agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease, Mol Genet Metab, vol.105, pp.221-227 ,
Hypoglossal neuropathology and respiratory activity in pompe mice, Front Physiol, vol.2, p.31, 2011. ,
Adjunctive beta2-agonists reverse neuromuscular involvement in murine Pompe disease, FASEB J, vol.27, pp.34-44, 2013. ,
Pompe's disease: an inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle, Acta Neuropathol, vol.23, pp.229-244, 1973. ,
Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2, Neurology, vol.57, pp.906-908, 2001. ,
Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates, Mol Ther, vol.23, pp.477-487, 2015. ,
Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy, Hum Gene Ther, vol.25, pp.619-630, 2014. ,
Adenoassociated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis, Mol Ther, vol.22, pp.498-510, 2014. ,
Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice, Mol Ther, vol.20, pp.21-27, 2012. ,
Enzyme replacement therapy in the mouse model of Pompe disease, Mol Genet Metab, vol.80, pp.159-169, 2003. ,
Targeted disruption of the acid alphaglucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II, J Biol Chem, vol.273, pp.19086-19092, 1998. ,
Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity, J Virol, vol.76, pp.791-801, 2002. ,
CRIM-negative infantile Pompe disease: 42-month treatment outcome, J Inherit Metab Dis, vol.33, pp.751-757, 2010. ,
Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates, Hum Gene Ther, vol.24, pp.526-532, 2013. ,
Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates, Hum Gene Ther, vol.23, pp.382-389, 2012. ,
, Vibrational Spectroscopy in Diagnosis and Screening. In: Advances in Biomedical Spectroscopy, vol.6, 2012.
Glycan binding avidity determines the systemic fate of adenoassociated virus type 9, J Virol, vol.86, pp.10408-10417, 2012. ,
Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency, J Biol Chem, vol.288, pp.28814-28823, 2013. ,
Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice, J Neuropathol Exp Neurol, vol.67, pp.803-818, 2008. ,
Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes, Hum Gene Ther, vol.24, pp.630-640, 2013. ,
Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: clinical evidence of respiratory plasticity, Exp Neurol, vol.287, pp.216-224, 2017. ,
Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy, Neurology, vol.80, p.1173, 2013. ,
Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy, Mol Ther, vol.16, pp.1366-1371, 2008. ,
Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II, Mol Ther, vol.14, pp.822-830, 2006. ,
Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II, Mol Ther, vol.11, pp.57-65, 2005. ,
Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings, Chang Gung Med J, vol.27, pp.379-384, 2004. ,
Characterization of pre-and posttreatment pathology after enzyme replacement therapy for Pompe disease, Lab Investig, vol.86, pp.1208-1220, 2006. ,
Correcting neuromuscular deficits with gene therapy in Pompe disease, Ann Neurol, vol.78, pp.222-234, 2015. ,
Transcriptome assessment of the Pompe (Gaa?/?) mouse spinal cord indicates widespread neuropathology, Physiol Genomics, vol.00075, p.2016, 2016. ,
Neuropathology in respiratory-related motoneurons in young Pompe (Gaa(?/?)) mice, Respir Physiol Neurobiol, vol.227, pp.48-55, 2016. ,
Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease, J Inherit Metab Dis, vol.38, pp.305-314, 2015. ,
Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy, J Inherit Metab Dis, vol.35, pp.505-511, 2012. ,
Assessment of toxicity and biodistribution of recombinant AAV8 vectormediated immunomodulatory gene therapy in mice with Pompe disease, 2014. ,
, Mol Ther Methods Clin Dev, vol.1, p.14018
Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis, Hum Mol Genet, vol.23, pp.668-681, 2014. ,
Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice, Gene Ther, vol.13, pp.917-925, 2006. ,
Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model, Gene Ther, vol.11, pp.1590-1598, 2004. ,
Auditory brainstem responses in 10 inbred strains of mice, Brain Res, vol.1091, pp.16-26, 2006. ,